Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation.

Autor: Amonoo HL; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Johnson PC; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., Dhawale TM; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., Traeger L; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., Rice J; Massachusetts General Hospital, Boston, Massachusetts., Lavoie MW; Massachusetts General Hospital, Boston, Massachusetts., Ufere NN; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., Longley RM; Massachusetts General Hospital, Boston, Massachusetts., Harnedy LE; Massachusetts General Hospital, Boston, Massachusetts., Clay MA; Massachusetts General Hospital, Boston, Massachusetts., Topping CEW; Massachusetts General Hospital, Boston, Massachusetts., DeFilipp Z; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., Chen YA; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts., El-Jawahri A; Harvard Medical School, Boston, Massachusetts.; Massachusetts General Hospital, Boston, Massachusetts.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2021 Apr 15; Vol. 127 (8), pp. 1260-1265. Date of Electronic Publication: 2021 Feb 17.
DOI: 10.1002/cncr.33455
Abstrakt: Background: Social support is crucial for successful recovery after hematopoietic stem cell transplantation (HSCT) and has the potential to affect patient quality of life (QOL) and health outcomes. However, there are limited data on the relationship between a patient's perception of his or her social support and these outcomes.
Methods: The authors conducted a secondary analysis of 250 autologous and allogeneic HSCT recipients enrolled in 2 supportive care trials at Massachusetts General Hospital from April 2011 through February 2016. They assessed social support as a patient's perception of his or her social well-being via the social well-being subscale of the Functional Assessment of Cancer Therapy. The authors used multivariate regression analyses to examine the relationship between pretransplant social well-being and QOL (Functional Assessment of Cancer Therapy-Treatment Outcome Index), psychological distress (Hospital Anxiety and Depression Scale), posttraumatic stress disorder [PTSD] symptoms (PTSD Checklist), fatigue (Functional Assessment of Cancer Therapy-Fatigue), and health care utilization (hospitalizations and days alive and out of the hospital) 6 months after HSCT.
Results: Participants were on average 56.4 years old (SD, 13.3 years); 44% (n = 110) and 56% (n = 140) received autologous and allogeneic HSCT, respectively. Greater pre-HSCT social well-being was associated with higher QOL (B = 0.10; 95% CI, 0.06-0.13; P < .001), lower psychological distress (B = -0.21; 95% CI, -0.29 to -0.12; P < .001), and lower PTSD symptoms (B = -0.12; 95% CI, -0.19 to -0.06; P < .001). Pre-HSCT social well-being was not significantly associated with fatigue or health care utilization 6 months after HSCT.
Conclusions: Patients with higher pre-HSCT perceptions of their social support reported better QOL and lower psychological distress 6 months after HSCT. These findings underscore the potential for social support as a modifiable target for future supportive care interventions to improve the QOL and care of HSCT recipients.
(© 2021 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: